This panel will discuss litigation developments in the biosimilars marketplace of interest to both biologics and biosimilar companies, including recent developments, such as Amgen v. Sandoz. The panel will also consider implications, as well as litigation strategies and best practices.
Panel Moderator: Uma Everett, Director
Panelist: Stuart Watt, Vice President, Law and Intellectual Property Officer, Amgen
Panelist: J.C. Rozendaal, Director
Panelist: Timothy J. Shea, Jr., Director